Refine by
Apoptosis Articles & Analysis
27 news found
Summary Attending a loupe fair is an exciting and essential milestone for dental and hygiene students. Loupes are a critical tool in modern dentistry, enhancing precision and ergonomics during procedures. Choosing the right pair of loupe and LED headlight can significantly impact your comfort and performance. Here’s a guide to help dental and hygiene students prepare for a loupe fair, ...
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its extensive portfolio of P53 and TP53 antibodies and solutions to support researchers in the critical field of cancer research. This comprehensive collection of research tools will empower scientists to advance their understanding of P53 and TP53 and their role in cancer development ...
Cytokine, a subdivision of Creative Proteomics, specializes in providing cytokine research and analytical services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Recently, the product manager of the company is pleased to announce the launch of the growth factors (GF) detection service for further research enhancement. ...
A valid alternative to liposuction is represented by Cryolipolysis, a non-invasive Aesthetic Medicine technique for body contouring. The Biotec Italia Medical team has patented Cryoliposculpt, an innovative device that stands out from other technologies on the market. This is a true evolution of cryolipolysis procedures, as also demonstrated by numerous scientific articles written on ...
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a Cellworks biosimulation pilot study, which examined the impact of mismatch repair deficiency (MRD) on survival of temozolomide (TMZ)-treated patients with MGMT methylated (m-MGMT) glioblastoma (GBM). The biosimulation study validated that TMZ does not trigger ...
Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRPα monoclonal antibody ES004, PD-L1/SIRPα bispecific antibody ...
An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cancer in Phase I/II TORCH-2 Study of ATG-008 (onatasertib) in combination with toripalimab, regardless of PD-L1 status Study builds on promising results of Phase II TORCH monotherapy study in HBV+ patients with unresectable hepatocellular carcinoma (HCC) which demonstrated an ORR of 16.7% in the 45 mg ...
Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, today announced it will have five poster presentations at the SITC 2022 Annual Meeting being held in Boston, Massachusetts from November 8-12. The posters will highlight preclinical studies on five ...
Upon closing of their proposed Business Combination, Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., and is expected to be listed on NASDAQ under the symbol, “OCEA”. Providence, RI and New York, NY, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. ...
Creative Biogene unveiled a rich portfolio of efficient cell apoptosis assay kits targeted to detect mitochondrial permeability transition pore (MPTP) as well as mitochondrial membrane potential (MMP) to assist researchers in mitochondrial studies. Mitochondrial dysfunction has been linked to a variety of market therapeutics and pathological diseases. Therefore, studying or maintaining ...
New York, United States—May 18, 2022—As one of leading bio-companies engaged in mitochondrial research, Creative Biogene, together with its large team of experts, create a powerful mitochondrial research service platform. To satisfy the research needs of global customers on mitochondrial bioenergies, Creative Biogene provides partners with comprehensive range of mitochondrial bioenergetics ...
It is estimated that more than 240,000 cases of brain and nervous system tumors are diagnosed each year around the world. The most common and most lethal of these cancerous tumors are glioblastoma (GBM). What is Glioblastoma? Glioblastoma is a type of glioma, which is a brain tumor that begins in the star-shaped glial cells that surround and support nerve cells in the brain. GBM is a Grade IV ...
Inflammatory bowel disease (IBD), mainly divided into Crohn's disease (CD) and ulcerative colitis (UC), are diseases whose causes are not fully understood and for which there is no cure. The chronic progression of IBD is characterized by periods of symptomatic relapses and symptom-free phases. During relapses, acute inflammation occurs in the bowel of IBD patients, leading to typical symptoms ...
UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, announced presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting featuring UBX1325 as a potential treatment for diabetic macular edema (DME) and wet age-related macular degeneration (AMD), as well ...
New York, United States—April 21, 2022—Defects in mitochondrial function have long been suspected of contributing to the development of cancer. In this regard, Creative Biogene strives to explore mitochondrial functions that are yet to be discovered as well as the pathogenesis of mitochondria-associated cancers and possible interventions through in-depth mitochondrial function testing ...
UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the first patient has been dosed in the ENVISION study, its Phase 2 clinical trial of UBX1325 in patients with wet age-related macular degeneration (wAMD). “The clinical and preclinical data generated so far ...
12-week safety and efficacy data anticipated by mid-year 2022 24-week safety and efficacy data anticipated before year-end 2022 UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, has completed enrollment for the BEHOLD study, its Phase 2 clinical trial of UBX1325 in patients with ...
24-week UBX1325 Phase 1 data presented at Angiogenesis, Exudation, and Degeneration 2022 Conference Patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) showed improvement in visual acuity through 24 weeks following single dose of UBX1325 Phase 2 clinical studies of UBX1325 currently enrolling patients with DME and wAMD UNITY Biotechnology, Inc. ...
CellworksGroup, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-023 clinical trial, which found that the Cellworks Biosimulation Platform with its Therapy Response Index (TRI) reliably predicts complete response (CR) and overall survival (OS) for individual Acute Myeloid Leukemia (AML) patients beyond ...
US Medical Innovations, LLC (USMI), a U.S. FDA-registered life-science and biomedical device company and the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) announced today that Jerome Canady MD, CEO will be presenting at the Baird Global Healthcare Conference on Tuesday, September 14th from 10:15 to 10:45 AM ET. Dr. Canady will present results ...